Caprice Greystoke
This article was originally published in The Tan Sheet
Executive Summary
Met with FDA on April 21 to discuss its appetite suppressant product Spray-U-Thin (phenylpropanolamine). The meeting was in response to a February warning letter from FDA that charged that Spray-U-Thin is a new drug not covered under the OTC weight control drug monograph "based on the dosage...and the method and duration of administration of the active ingredient." FDA also cited misleading labeling claims and several good manufacturing practices infractions in the letter. Caprice Greystoke said it is continuing to manufacture and market the product while it attempts to address FDA's concerns
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning